With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

Air pollution has become a never ending problem world wide affecting the healths of millions. While its impact on respiratory and cardiovascular health is well-documented, emerging research ...

Righting the ship on supply Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive signals” are emerging when it comes to the ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes ...

Drug giant Novo Nordisk just reported some clinical trial data. Despite the seemingly good news, the stock crashed right afterward. There's a difference between a clinical success and a ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $85 per share, more than 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock (NYSE:LLY ...

Novo Nordisk A/S (NVO) investors were hit by a train as the leading diabetes and obesity drugs maker's recent CagriSema study didn't impress as its performance came in markedly below its ...

CEO Lars Fruergaard Joergensen delivers a statement during a presentation of the new production site ... [+] of Novo Nordisk "Site Odense" in Kroghs park in Odense, Denmark, on December 16, 2024 ...

Haemophilia is a rare condition that affects the blood’s ability to clot. Credit: Rembolle via Shutterstock. Novo Nordisk has secured approval from the US Food and Drug Administration (FDA) for Alhemo ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...